openPR Logo
Press release

Werum’s MES PAS-X is part of Novo Nordisk’s first combined ERP/MES system

12-10-2011 02:07 AM CET | IT, New Media & Software

Press release from: Werum Software & Systems AG

Filling of modern insulin in vials at Novo Nordisk’s site in Hillerød, Denmark

Filling of modern insulin in vials at Novo Nordisk’s site in Hillerød, Denmark

Werum’s MES PAS-X is part of Novo Nordisk’s first combined ERP/MES system
Rollout in Denmark is important milestone in one of the biggest IT programs in Novo Nordisk’s history

Lueneburg, Germany, 6 December 2011 – In the framework of the global PS@SAP program, Accenture, Werum Software & Systems, and NNE Pharmaplan have rolled out the first combined ERP/MES system at Novo Nordisk’s site in Denmark.

The main objective of the program is to implement a globally standardized ERP/MES solution on the basis of SAP and Werum’s PAS-X. The program is intended to be rolled out later to most of Novo Nordisk’s worldwide manufacturing sites.

Novo Nordisk decided on Werum’s PAS-X because it provides essential functionalities out-of-the-box. Another factor that convinced Novo Nordisk to choose Werum’s manufacturing execution system is the fact that PAS-X has a proven record of successful installations throughout the industry.

The program started with the development of a standalone PAS-X pilot system in Denmark in 2008 and with some other implementations throughout the organization. Since then, Novo Nordisk, Werum and NNE Pharmaplan have been cooperating closely and have designed and implemented a MES PAS-X Core system.

About Werum Software & Systems AG
With over 40 years of software development experience, Werum Software & Systems AG is known worldwide for partnering with its global customers to create state-of-the-art software products and solutions. Internationally networked teams of top experts develop software solutions for corporate groups known the world over. Werum is an internationally leading supplier of Manufacturing Execution Systems (MES) for the pharmaceutical and biopharmaceutical industries. Its successful and well-established MES product PAS-X is used by 16 of the world’s top 30 pharmaceutical and biotech companies in more than 550 installations. Founded in 1969, the IT company employs about 450 people at its headquarters in Lueneburg, Germany, and at eight other locations in Germany, France, the United States, Japan, and Singapore. For more information take a look at our website at www.werum.com and www.pas-x.com.

Dirk Ebbecke
Director Corporate Communications
Werum Software & Systems AG
Wulf-Werum-Strasse 3
21337 Lueneburg, Germany
Tel. +49 4131 8900-689
Fax +49 4131 8900-20
dirk.ebbecke@werum.com

For further information, visit Werum’s press center at www.press.werum.com.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Werum’s MES PAS-X is part of Novo Nordisk’s first combined ERP/MES system here

News-ID: 203092 • Views: 1496

More Releases from Werum Software & Systems AG

Research Made Easy
With their web-based data management system DSHIP the German-based company Werum Software & Systems supports maritime research on board of research vessels all over the world. The Instagram profile of the current climate research expedition MOSAiC in the North Polar Sea shows straightaway: research work on the high seas may be really fascinating, but it also is extremely laborious, fragmented and highly complex. As they depend on the various environmental conditions
Werum’s "PAS-X Reports & Labels" Content Packages significantly reduce MES imp …
Werum’s "PAS-X Reports & Labels" Content Packages significantly reduce MES implementation times Best practice consulting services and “Out of the Box”-templates for GMP-compliant reports and labels Lueneburg, Germany, 29 January 2014 – By providing "PAS-X Reports & Labels" Content Packages, Werum Software & Systems now offers an even broader range of pre-configured reports and labels along with the associated comprehensive consulting services to its customers. These packages are based on best practices
Werum accelerates MBR creation by providing "PAS-X MBR Design Elements" Content …
Werum accelerates MBR creation by providing "PAS-X MBR Design Elements" Content Packages New "PAS-X MBR Design Elements" Content Packages based on industry best practice / process-specific and fast MBR creation for pharmaceutical production Lueneburg, Germany, 28 November 2013 – In order for pharma and biotech customers to implement PAS-X MES projects even faster and more easily, Werum Software & Systems expands its PAS-X Content Packages offering further: New on the market are
Werum equips research vessel Mya II of Alfred Wegener Institute with DSHIP softw …
Werum equips research vessel Mya II of Alfred Wegener Institute with DSHIP software AWI puts new RV Mya II into service / Werum's data management system DSHIP ensures acquisition, archiving and evaluation of measurement data Lueneburg, Germany, 23 October 2013 – The new RV Mya II, which has only recently been delivered to the German Alfred Wegener Institute, Helmholtz Center for Polar and Marine Research (AWI), has been equipped by Werum Software

All 5 Releases


More Releases for Novo

Diabetes Therapeutic Market Innovations, Competitive Analysis, New Business Deve …
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries
Growth Hormone Deficiency Therapeutics- Pipeline Analysis 2018 | Novo Nordisk
Growth hormone deficiency is a congenital or acquired hormonal disorder, that is characterized by short stature due to lack of growth hormone. The disease can cause change in muscle mass, bone strengths, and cholesterol levels. Download the sample report @ https://www.pharmaproff.com/request-sample/1076 This condition is found to be related to the mutation in POU1F1/Pit1, PROP1 GHRH and GH1 genes. Puberty is generally delayed or absent in adolescents with growth hormone deficiency. Get the
Hormonal Replacement Therapeutics - Pipeline Analysis 2018 | Novo Nordisk
Hormonal replacement therapy is a type of treatment wherein patients receive a course of hormones in order to get relieve from the menopause related problems. The therapy involves administration of synthetic estrogen and progesterone to overcome decreasing hormone level of women. Download the sample report @ https://www.pharmaproff.com/request-sample/1136 The most common signs and symptoms observed in patients with decreased hormone level are irregular menstrual cycles, and psychological symptoms (mood swings, anxiety, and
Antidiabetics Market Size, Historical Growth Analysis By top Key Player - Boehri …
Market Study Report: The Report entitled 2018-2024 Global Antidiabetics Market Report explores the essential factors of the Antidiabetics market considering such as industry situations, market demands, market players adopted business strategies and their growth scenario. The Global Antidiabetics market has been separated by this report based on the key players profiles, Type, Application and Regions. Germany antidiabetics industry accounted for largest revenue size of USD 4,461.7 million of Europe antidiabetics industry
Global Recombinant DNA Technology Market 2025 : Monsanto Company, Pfizer Inc., N …
Researchmoz added Most up-to-date research on "Global Recombinant DNA Technology Market Size,Status and Forecast 2025" to its huge collection of research reports. This report studies the global Recombinant DNA Technology market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Recombinant DNA Technology market by companies, region, type and end-use industry. In 2017, the global Recombinant DNA Technology market size was million US$ and it
Global Liraglutide Injection Market 2018 - Novo Nordisk
Apex Market Reports, recently published a detailed market research study focused on the “Liraglutide Injection Market” across the global, regional and country level. The report provides 360° analysis of “Liraglutide Injection Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Liraglutide Injection on